Funding · Biotech
Tempo Therapeutics raises $14.5m for regenerative-medicine research and operations
The financing backs development of its MAP biomaterial platform and lead cell-free candidate TT101.
Tempo Therapeutics raised $14.5 million from investors including Galaxy Sirius Partners, Johnson & Johnson Innovation–JJDC, Gideon Strategic Partners, Mesa Verde Venture Partners and YK Bioventures.
The company plans to expand operations and research and development. Its MAP technology forms injectable microporous scaffolds designed to support tissue repair, with TT101 as the lead cell-free candidate.
Use of funds
Expand operations and research and development
Funding history
Funding · This round$14.5M